A Randomized-open-label-five-period-balanced-crossover Study to Evaluate the Relative Bioavailability of an Eltrombopag PfOS Formulation Relative to the 25 mg Tablet Formulation and to Evaluate Administration of the PfOS Formulation With and Separated 2 Hours From a High Calcium Meal in HV

Trial Profile

A Randomized-open-label-five-period-balanced-crossover Study to Evaluate the Relative Bioavailability of an Eltrombopag PfOS Formulation Relative to the 25 mg Tablet Formulation and to Evaluate Administration of the PfOS Formulation With and Separated 2 Hours From a High Calcium Meal in HV

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Oct 2014

At a glance

  • Drugs Eltrombopag (Primary) ; Eltrombopag
  • Indications Idiopathic thrombocytopenic purpura
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 15 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top